特一药业：2025年净利同比预增241.55%-339.13%

Core Viewpoint - The company expects a net profit attributable to shareholders of 70 million to 90 million yuan for the fiscal year 2025, representing a year-on-year growth of 241.55% to 339.13% [1] Group 1: Performance Drivers - The current performance change is attributed to the deepening of marketing transformation, advancement of brand strategy, and product recovery [1] - Core product sales have rebounded, and marketing channel optimization has contributed to a good recovery in both operating revenue and overall gross profit margin [1] Group 2: Financial Impact - Despite short-term impacts on profits due to investments in brand building, the overall operating profit has shown positive improvement [1] - The results reflect that marketing reforms and brand development have achieved significant effectiveness [1]